|

Lifileucel Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: AMTAGVI, LN-144, LN-144/LN-145, TIL, autologous tumor infiltrating lymphocytes, lifileucel, TIL, Tumor-Infiltrating Lymphocytes

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Iovance Biotherapeutics, Inc.3
  • Immatics US, Inc.1

Indications

  • Cancer4
  • Metastatic Melanoma2
  • Melanoma, Cutaneous Malignant1
  • Melanoma (Skin Cancer)1
  • Squamous Cell Carcinoma of the Head and Neck1

Phoenix, Arizona2 trials

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Honor Health

Phase 2
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

La Jolla, California1 trial

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

University of California, San Diego

Phase 2

Nashville, Tennessee1 trial

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Sarah Cannon Research Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.